A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- BioNTech SE
- 入组人数
- 1,438
- 试验地点
- 102
- 主要终点
- Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)
研究概览
简要总结
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.
详细描述
Both parts (Part 1 and Part 2) will start enrolling study participants independent of each other.
In Part 1, participants with histologically or cytologically confirmed advanced solid tumors will receive BNT326 monotherapy in the following cohorts:
- Cohort 1A: Cutaneous melanoma (second-line or higher treatment [2L+]).
- Cohort 1B: Actionable oncogenic alterations (AGA)-negative non-small cell lung cancer (NSCLC) 2L+.
- Cohort 1C: Epidermal growth factor receptor mutated (EGFRm) NSCLC 2L+.
- Cohort 1D: Rare melanoma (acral/uveal/mucosal melanoma) 2L+.
- Cohort 1E: Other advanced solid tumors 2L+.
- Cohort 1F (drug-drug interaction [DDI] Cohort): Advanced solid tumors.
- Cohort 1G: Cervical cancer 2L+.
In Part 2, BNT326 will be studied as monotherapy or in combination with other immunotherapeutic agents. The first combination treatment will be BNT326 with BNT327 (also known as pumitamig or PM8002). The following cohorts are planned:
- Cohort 2A: BNT326 + pumitamig for cutaneous melanoma 2L+.
- Cohort 2B: BNT326 + pumitamig for human epidermal growth factor receptor 2 (HER2)-negative breast cancer 2L+/first line treatment (1L).
- Cohort 2C (Optional): BNT326 + pumitamig for cutaneous melanoma first-line or higher treatment (1L+). This cohort may be added if BNT326 + pumitamig for cutaneous melanoma 2L+ is tolerated, and shows signs of efficacy.
- Cohort 2D: BNT326 + pumitamig for gastric cancer (GC)/gastroesophageal junction cancer (GEJC) 2L+.
- Cohort 2E: BNT326 + pumitamig for colorectal cancer 2L+.
- Cohort 2F: BNT326 + pumitamig for cervical cancer 2L+.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(applicable to all participants and all parts unless otherwise specified):
- •Aged ≥18 years at the time of giving informed consent. Local laws will be followed if the age of consent is older.
- •Have histologic or cytologic documented advanced disease, either at relapse or upon diagnosis of metastatic disease. This requirement may be considered met when advanced disease derives from unequivocal progression of a previously biopsied site of disease (e.g., progression of residual tumor after concomitant chemo-radiation for Stage III NSCLC).
- •Have measurable disease defined by RECIST v1.
- •Have ECOG performance status of 0 or
- •Have adequate organ and bone marrow function (as specified in the protocol) within 7 days before randomization/enrollment.
- •Cohort 1A:
- •Have histologically or cytologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma not amenable to local therapy.
- •Participants must have previously received a PD-1 or PD-L1 inhibitor, and, for participants with human gene that encodes a protein called B-Raf (BRAF) gene mutant melanoma, a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene inhibitor with or without mitogen-activated protein kinase protein inhibitor, if available and clinically indicated per local standard of care (SoC) and have experienced progression during or after the previous treatment or discontinued from prior therapy due to intolerance.
- •Cohort 1B and 1C: Have advanced (i.e., metastatic or locally recurrent where local therapy with curative intent is not possible) non-squamous or squamous NSCLC.
- •Cohort 1B:
- •Have no actionable genomic alterations, such as EGFR mutations, anaplastic lymphoma kinase rearrangements, or other genomic alterations for which targeted molecular therapies are available. For enrolled participants with predominantly squamous histology tumors, molecular testing will not be required in cases where it is not part of the SoC.
- •Have experienced relapse or progression during or after treatment with standard systemic therapy including platinum-based chemotherapy and/or immune checkpoint inhibitor in the advanced/metastatic setting or discontinued from prior therapy due to intolerance.
- •Participants must have received 1 to 3 lines of systemic treatment in the metastatic setting, which can include anti-PD-1/PD-L1 therapy (if PD-L1 positive), chemotherapy, and anti-angiogenic agents. These treatments may be administered concurrently or sequentially. Prior chemotherapy must be limited to 2 lines or less.
- •Cohort 1C:
- •Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).
- •Participants must have received one or two prior lines of systemic therapy for advanced and/or metastatic disease, which must include treatment with an approved EGFR Tyrosine Kinase Inhibitors (TKI), with at least one being a third-generation EGFR TKI. If there is no third-generation EGFR TKI approved as part of SoC by local health authorities in a certain country, failure/progression on any EGFR TKI is acceptable for eligibility.
- •Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day
- •Prior chemotherapy and amivantamab are permitted only if administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first-line) treatment for advanced/metastatic disease. Participants must not have received any other systemic therapies (such as chemotherapy, immunotherapy, or targeted agents) for advanced/metastatic disease, unless those treatments were given in combination with an EGFR TKI.
- •Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.
- •Cohort 1D:
- •Have histologically or cytologically confirmed diagnosis of unresectable or metastatic acral/uveal/mucosal melanoma not amenable to local therapy.
- •Participants must have:
- •Previously been treated with a PD-1 or PD-L1 inhibitor, if clinically indicated and available per local SoC, and/or
- •For participants with Human Leukocyte Antigen Alleles (HLA-A)*02:01 serotype-positive disease (only applicable for uveal melanoma), previously been treated with tebentafusp-tebn if clinically indicated and available per local SoC, and
- •Experienced progression during or after the previous treatment or discontinued from prior therapy due to intolerance.
- •Cohorts 1E and 1F (DDI):
- •Have histologically or cytologically confirmed diagnosis of unresectable or metastatic advanced solid tumor not amenable to ablative or curative approach including, but not limited to:
- •Cholangiocarcinoma, including tumors of the intra- and extrahepatic biliary tract and gallbladder
- •Hepatocellular carcinoma (HCC).
- •Renal cell carcinoma
- •Endometrial carcinoma, excluding those classified as true sarcomas
- •Pancreatic ductal adenocarcinoma (PDAC) (see below other related inclusion criterion)
- •Neuroendocrine tumor of pancreatic, gastrointestinal, lung, and thymus that is well differentiated, Grade 1 to
- •NSCLC (Cohort 1F only)
- •Have experienced disease progression on at least one and no more than three lines of prior therapy or, for Cohort 1E only, discontinued from prior therapy due to intolerance.
- •(For participants with PDAC only) Have received one or two lines of systemic therapy for metastatic tumors, and have experienced progression or intolerance to the treatment during or following therapy.
- •Cohort 2A: Have histologically or cytologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma not amenable to local therapy.
- •Cohort 2B: Have histologically or cytologically confirmed diagnosis of recurrent unresectable or metastatic breast cancer that is documented as HER2-negative and either HR-negative or HR-positive per American Society of Clinical Oncology/College of American Pathologists guidelines.
- •Cohort 2D:
- •Histologically and/or cytologically documented metastatic adenocarcinoma and squamous carcinoma of GC/GEJC. (Note: Esophageal squamous-cell carcinoma is excluded).
- •(2L subgroup): Had disease progression during or after one prior line of anti-cancer therapy for recurrent/metastatic disease.
- •(3L subgroup): Has received two or more lines of prior anti-cancer therapy for recurrent/metastatic disease.
- •(HER2-expression positive subgroup): Has received at least one prior line of systemic therapy for recurrent or metastatic disease, including a HER2-targeted agent in accordance with local SoC.
- •Cohort 2E:
- •Histologically and/or cytologically documented recurrent unresectable metastatic colorectal adenocarcinoma.
- •Must have received at least one line to a maximum of three lines of prior SoC treatment for recurrent/metastatic disease.
- •Cohort 1G and 2F:
- •Histologically and/or cytologically documented recurrent unresectable metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology.
- •Must have received platinum-based chemotherapy, with or without an anti-PD-(L)1 agent and bevacizumab for metastatic/recurrent disease, unless the patient is not a candidate in the opinion of the treating physician.
排除标准
- •(applicable to all participants and all parts unless otherwise specified):
- •Have a history of intolerance to treatment with a topoisomerase I inhibitor or intolerance to an ADC that consists of a topoisomerase I inhibitor, including but not limited to topotecan, irinotecan, and deruxtecan (e.g., severe diarrhea).
- •Have an uncontrolled concomitant or intercurrent illness that contra-indicates study participation, limits compliance with study procedures or substantially increases the risk of incurring adverse events, including:
- •Bleeding diathesis or active hemorrhage,
- •Active infection,
- •Child-Pugh class B or C cirrhosis,
- •Known pulmonary disease with significant impact in lung function
- •Oncologic emergencies or complications (e.g., malignant hypercalcemia, superior vena cava syndrome, carcinoid syndrome that is unstable and with available alternative therapies),
- •Psychiatric or abuse condition
- •Infectious colitis Grade ≥2 not resolved to Grade 1 within 72 hours within the past 3 months.
- •Have LVEF <50% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment.
- •Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization/enrollment.
- •Have a history of (non-infectious) interstitial lung disease (ILD) /pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Asymptomatic interstitial changes caused by previous radiation therapy, chemotherapy, or other factors such as smoking are acceptable.
- •Are a participant of child-bearing potential who are pregnant or breastfeeding or are planning pregnancy within 225 days (~7.5 months) after receiving last dose of BNT326 and within 6 months after last dose of pumitamig, whichever is longer.
- •Are potentially fertile males, who are planning to father children during the study or within 135 days (~4.5 months) after the last dose of BNT326 and within 6 months after last dose of pumitamig, whichever is longer.
- •Are subject to exclusion periods from another investigational study.
- •Specific to pumitamig: Participants with significant risks of hemorrhage or evidence of major coagulation disorders as specified in the protocol.
- •Specific to pumitamig: Have a history of intolerance to treatment with an anti-vascular endothelial growth factor, anti-PD-1/PDL-1, or similar substance, including, but not limited to, bevacizumab, ramucirumab, atezolizumab, pembrolizumab, nivolumab, or other related therapies.
- •Cohort 1E: Have histological diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
- •NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
研究组 & 干预措施
Part 1 (Cohort 1E) - BNT326 monotherapy
BNT326 (DL2) in participants with advanced solid tumors 2L+
干预措施: BNT326 (Drug)
Part 1 (Cohort 1B) - BNT326 monotherapy
BNT326 (DL1 or DL2) in participants with NSCLC 2L+ AGA-negative
干预措施: BNT326 (Drug)
Part 1 (Cohort 1C) - BNT326 monotherapy
BNT326 (DL1 or DL2) in participants with NSCLC 2L+ EGFRm
干预措施: BNT326 (Drug)
Part 1 (Cohort 1D) - BNT326 monotherapy
BNT326 (DL2 or DL3) in participants with rare melanoma 2L+
干预措施: BNT326 (Drug)
Part 1 (Cohort 1A) - BNT326 monotherapy
BNT326 (DL1 or DL2 or DL3) in participants with cutaneous melanoma 2L+
干预措施: BNT326 (Drug)
Part 1 (Cohort 1F, DDI) - BNT326 + paroxetine
BNT326 (DL1 or DL2 or DL3) + paroxetine in participants with advanced solid tumors
干预措施: Paroxetine (Drug)
Part 1 (Cohort 1F, DDI) - BNT326 + paroxetine
BNT326 (DL1 or DL2 or DL3) + paroxetine in participants with advanced solid tumors
干预措施: BNT326 (Drug)
Part 2 (Cohort 2E1) - BNT326 monotherapy
BNT326 (DL2) in participants with colorectal cancer 2L+
干预措施: BNT326 (Drug)
Part 2 (Cohort 2D1) - BNT326 monotherapy
BNT326 (DL2) in participants with GC/GEJC 2L+
干预措施: BNT326 (Drug)
Part 2 (Cohort 2F) - BNT326 + pumitamig
Combination therapy of BNT326 with pumitamig in participants with cervical cancer 2L+ (BNT326 DL2 with pumitamig DL1 or DL2 or BNT326 DL3 with pumitamig DL1 or DL2)
干预措施: Pumitamig (Drug)
Part 2 (Cohort 2B dose escalation) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L
干预措施: Pumitamig (Drug)
Part 2 (Cohort 2B dose randomization/expansion) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L
干预措施: Pumitamig (Drug)
Part 2 (Cohort 2B dose escalation) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L
干预措施: BNT326 (Drug)
Part 2 (Cohort 2A dose randomization/expansion) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.
干预措施: BNT326 (Drug)
Part 2 (Cohort 2D2) - BNT326 + pumitamig
Combination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with GC/GEJC 2L+
干预措施: BNT326 (Drug)
Part 2 (Cohort 2B dose randomization/expansion) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L
干预措施: BNT326 (Drug)
Part 1 (Cohort 1G) - BNT326 monotherapy
BNT326 (DL2 or DL3) in participants with cervical cancer 2L+
干预措施: BNT326 (Drug)
Part 2 (Cohort 2E2) - BNT326 + pumitamig
Combination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with colorectal cancer 2L+
干预措施: BNT326 (Drug)
Part 2 (Cohort 2F) - BNT326 + pumitamig
Combination therapy of BNT326 with pumitamig in participants with cervical cancer 2L+ (BNT326 DL2 with pumitamig DL1 or DL2 or BNT326 DL3 with pumitamig DL1 or DL2)
干预措施: BNT326 (Drug)
Part 2 (Cohort 2E2) - BNT326 + pumitamig
Combination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with colorectal cancer 2L+
干预措施: Pumitamig (Drug)
Part 2 (Cohort 2D2) - BNT326 + pumitamig
Combination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with GC/GEJC 2L+
干预措施: Pumitamig (Drug)
Part 2 (Cohort 2C) - Optional - BNT326 + pumitamig
Combination therapy of BNT326 + pumitamig in participants with cutaneous melanoma 1L+
干预措施: Pumitamig (Drug)
Part 1 (Cohort 1F, DDI) - BNT326 + itraconazole
BNT326 (DL1 or DL2 or DL3) + itraconazole in participants with advanced solid tumors
干预措施: BNT326 (Drug)
Part 2 (Cohort 2A dose escalation) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.
干预措施: Pumitamig (Drug)
Part 2 (Cohort 2A dose randomization/expansion) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.
干预措施: Pumitamig (Drug)
Part 2 (Cohort 2C) - Optional - BNT326 + pumitamig
Combination therapy of BNT326 + pumitamig in participants with cutaneous melanoma 1L+
干预措施: BNT326 (Drug)
Part 1 (Cohort 1F, DDI) - BNT326 + itraconazole
BNT326 (DL1 or DL2 or DL3) + itraconazole in participants with advanced solid tumors
干预措施: Itraconazole (Drug)
Part 2 (Cohort 2A dose escalation) - BNT326 + pumitamig
Combination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.
干预措施: BNT326 (Drug)
结局指标
主要结局
Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)
时间窗: from first dose of investigational medicinal product (IMP) up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).
Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs
时间窗: from first dose of IMP up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2)
Part 2 - Occurrence of dose limiting toxicities (DLTs)
时间窗: from the time of initiation of the first dose of IMP up to 21 days
During the DLT observation period.
Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)
时间窗: from first dose of investigational medicinal product (IMP) up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).
Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs
时间窗: from first dose of IMP up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2)
Parts 1 and 2 - All cohorts except Cohort 1F - Confirmed overall response rate (ORR)
时间窗: from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)
Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) based on the investigator's assessment (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) is observed as best overall response. By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).
Part 2 - Occurrence of dose limiting toxicities (DLTs)
时间窗: from the time of initiation of the first dose of IMP up to 21 days
During the DLT observation period.
Part 1 - Cohort 1F (DDI) only - PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT326 and unconjugated payload
时间窗: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose
Evaluation of Cmax without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.
Part 1 - Cohort 1F (DDI) only - PK assessment: Area under the curve (AUC) over the last 17-day dosing interval derived from serum concentrations of BNT326 and unconjugated payload
时间窗: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose
Evaluation of AUC over the last 17-day dosing interval without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.
Parts 1 and 2 - All cohorts except Cohort 1F - Confirmed overall response rate (ORR)
时间窗: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)
Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) based on the investigator's assessment (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) is observed as best overall response. By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).
Part 1 - Cohort 1F (DDI) only - PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT326 ADC and unconjugated payload
时间窗: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose
Evaluation of Cmax without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.
Part 1 - Cohort 1F (DDI) only - PK assessment: Area under the curve (AUC) over the last 17-day dosing interval derived from serum concentrations of BNT326 ADC and unconjugated payload
时间窗: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose
Evaluation of AUC over the last 17-day dosing interval without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.
次要结局
- Part 1 - Cohort 1F (DDI) only - Occurrence of TEAEs, TRAEs, TESAEs, and TRSAEs(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for vital signs(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for clinical laboratory tests(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for cardiac function(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for Eastern Cooperative Oncology Group performance status (ECOG PS)(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload(from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2))
- Part 1 - Cohort 1F (DDI) only - Occurrence of TEAEs, TRAEs, TESAEs, and TRSAEs(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for vital signs(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for clinical laboratory tests(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for cardiac function(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for Eastern Cooperative Oncology Group performance status (ECOG PS)(from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP)
- Parts 1 and 2 - All cohorts - Progression-free survival (PFS) based on investigator's assessment(from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2))
- Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Cmax derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload(from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2))
- Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: AUC derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload(from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2))
- Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload(from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2))
- Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload(from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2))
- Parts 1 and 2 - All cohorts - Anti-drug antibody (ADA) prevalence and ADA incidence(up to 1 year from the last dose of IMP)
- Parts 1 and 2 - All cohorts - Anti-drug antibody (ADA) prevalence and ADA incidence(up to 1 year from the last dose of IMP)
- Parts 1 and 2 - All cohorts - Progression-free survival based on investigator's assessment(from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2))
- Parts 1 and 2 - All cohorts - Depth of response(from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2))
- Parts 1 and 2 - All cohorts - Disease control rate(from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2))
- Parts 1 and 2 - All cohorts - Duration of response(from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2))
- Parts 1 and 2 - All cohorts - Time to response(from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2))
- Parts 1 and 2 - All cohorts - Overall survival(from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2))